Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 22, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Molecular testing in malignant melanoma.

Allie H Grossmann1, Kenneth F Grossmann, Michelle L Wallander

  • 1Department of Pathology, ARUP Laboratories, University of Utah, Salt Lake City, Utah, USA.

Diagnostic Cytopathology
|May 24, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Pattern of Nuclear Staining With ROS1 Immunohistochemistry: A Case Report.

Case reports in pulmonology·2026
Same author

Racial differences in pathologic complete response rate and clinical outcomes following neoadjuvant chemotherapy for breast cancer.

Breast cancer research and treatment·2026
Same author

Rapid activation of ARF6 after RAF inhibition augments BRAF<sup>V600E</sup> and promotes therapy resistance.

Oncogene·2026
Same author

Baseline Body Composition Characteristics and Overall Survival in Young Women with Breast Cancer: Matched Case-Control Study Nested Within a Cohort.

Tomography (Ann Arbor, Mich.)·2026
Same author

Assessment of Surgical Approach and Overall Survival in Young Women With Breast Cancer.

European journal of breast health·2026
Same author

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.

Nature cancer·2026

Molecular testing for BRAF and KIT mutations is crucial for stage IV melanoma treatment. This review details clinically relevant mutations, their relation to melanoma subtypes, and testing recommendations.

Area of Science:

  • Oncology
  • Pathology
  • Genetics

Background:

  • Molecular testing is standard for cancer therapy selection, significantly impacting pathology.
  • Advances in BRAF and KIT inhibitors for metastatic melanoma have driven demand for molecular diagnostics.
  • Emerging research identifies new therapeutic targets and resistance mechanisms, necessitating broader molecular profiling.

Purpose of the Study:

  • To review clinically relevant mutations guiding systemic therapy in Stage IV melanoma.
  • To examine how molecular alterations vary by melanoma subtype and primary tumor site.
  • To offer practical recommendations for molecular testing strategies.

Main Methods:

  • Literature review of current research on melanoma molecular targets.
  • Analysis of mutation prevalence across different melanoma subtypes and primary sites.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Experiment Videos

Last Updated: May 22, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

  • Synthesis of data to inform testing guidelines.

    • Main Results:

    • Current routine testing focuses on BRAF and KIT mutations, which are found in distinct melanoma subsets.
    • Numerous molecular targets are under investigation, promising expanded therapeutic options.
    • Understanding mutation patterns is key to selecting appropriate targeted therapies.

    Conclusions:

    • Molecular testing is essential for personalized therapy in Stage IV melanoma.
    • Testing strategies must adapt to evolving knowledge of melanoma genetics and targeted treatments.
    • Comprehensive molecular profiling will likely become standard for melanoma management.